
## **Charles S Fuchs**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7938953/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet, The, 2014, 383, 31-39.	13.7	1,833
2	Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer. JAMA Oncology, 2018, 4, e180013.	7.1	1,350
3	Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet, The, 2018, 392, 123-133.	13.7	984
4	Analysis of <i>Fusobacterium</i> persistence and antibiotic response in colorectal cancer. Science, 2017, 358, 1443-1448.	12.6	983
5	Prospective Study of Predictors of Vitamin D Status and Cancer Incidence and Mortality in Men. Journal of the National Cancer Institute, 2006, 98, 451-459.	6.3	922
6	Physical Activity and Survival After Colorectal Cancer Diagnosis. Journal of Clinical Oncology, 2006, 24, 3527-3534.	1.6	762
7	Aspirin and the Risk of Colorectal Cancer in Relation to the Expression of COX-2. New England Journal of Medicine, 2007, 356, 2131-2142.	27.0	692
8	Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma. Cell Reports, 2016, 15, 857-865.	6.4	671
9	Impact of Physical Activity on Cancer Recurrence and Survival in Patients With Stage III Colon Cancer: Findings From CALGB 89803. Journal of Clinical Oncology, 2006, 24, 3535-3541.	1.6	664
10	Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer. JAMA Oncology, 2020, 6, 1571.	7.1	611
11	Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nature Genetics, 2009, 41, 986-990.	21.4	597
12	A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. Nature Genetics, 2010, 42, 224-228.	21.4	539
13	<i>Fusobacterium nucleatum</i> and T Cells in Colorectal Carcinoma. JAMA Oncology, 2015, 1, 653.	7.1	498
14	Aspirin Use and Survival After Diagnosis of Colorectal Cancer. JAMA - Journal of the American Medical Association, 2009, 302, 649.	7.4	497
15	Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field. Gut, 2011, 60, 397-411.	12.1	453
16	Sensitive Sequencing Method for KRAS Mutation Detection by Pyrosequencing. Journal of Molecular Diagnostics, 2005, 7, 413-421.	2.8	448
17	RNF43 is frequently mutated in colorectal and endometrial cancers. Nature Genetics, 2014, 46, 1264-1266.	21.4	388
18	Cancer Susceptibility Gene Mutations in Individuals With Colorectal Cancer. Journal of Clinical Oncology, 2017, 35, 1086-1095.	1.6	383

#	Article	IF	CITATIONS
19	Prospective Study of Fruit and Vegetable Consumption and Incidence of Colon and Rectal Cancers. Journal of the National Cancer Institute, 2000, 92, 1740-1752.	6.3	369
20	Association of Dietary Patterns With Cancer Recurrence and Survival in Patients With Stage III Colon Cancer. JAMA - Journal of the American Medical Association, 2007, 298, 754.	7.4	369
21	Genetic Mechanisms of Immune Evasion in Colorectal Cancer. Cancer Discovery, 2018, 8, 730-749.	9.4	367
22	Precision and Performance Characteristics of Bisulfite Conversion and Real-Time PCR (MethyLight) for Quantitative DNA Methylation Analysis. Journal of Molecular Diagnostics, 2006, 8, 209-217.	2.8	361
23	Evaluation of Markers for CpG Island Methylator Phenotype (CIMP) in Colorectal Cancer by a Large Population-Based Sample. Journal of Molecular Diagnostics, 2007, 9, 305-314.	2.8	296
24	Genome-wide association study identifies multiple susceptibility loci for pancreatic cancer. Nature Genetics, 2014, 46, 994-1000.	21.4	294
25	Phase II and Pharmacodynamic Study of Autophagy Inhibition Using Hydroxychloroquine in Patients With Metastatic Pancreatic Adenocarcinoma. Oncologist, 2014, 19, 637-638.	3.7	292
26	Influence of body mass index on outcomes and treatmentâ€related toxicity in patients with colon carcinoma. Cancer, 2003, 98, 484-495.	4.1	285
27	Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion. Nature Genetics, 2011, 43, 964-968.	21.4	270
28	Development and Validation of an Empirical Dietary Inflammatory Index. Journal of Nutrition, 2016, 146, 1560-1570.	2.9	263
29	Impact of Body Mass Index and Weight Change After Treatment on Cancer Recurrence and Survival in Patients With Stage III Colon Cancer: Findings From Cancer and Leukemia Group B 89803. Journal of Clinical Oncology, 2008, 26, 4109-4115.	1.6	245
30	Association of Dietary Patterns With Risk of Colorectal Cancer Subtypes Classified by <i>Fusobacterium nucleatum</i> in Tumor Tissue. JAMA Oncology, 2017, 3, 921.	7.1	243
31	Common variation at 2p13.3, 3q29, 7p13 and 17q25.1 associated with susceptibility to pancreatic cancer. Nature Genetics, 2015, 47, 911-916.	21.4	224
32	Genome-wide association analysis identifies TXNRD2, ATXN2 and FOXC1 as susceptibility loci for primary open-angle glaucoma. Nature Genetics, 2016, 48, 189-194.	21.4	211
33	Insulin, the Insulin-Like Growth Factor Axis, and Mortality in Patients With Nonmetastatic Colorectal Cancer. Journal of Clinical Oncology, 2009, 27, 176-185.	1.6	208
34	Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial. Lancet Oncology, The, 2019, 20, 1109-1123.	10.7	193
35	Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2019, 20, 420-435.	10.7	191
36	Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer. Nature Communications, 2018, 9, 556.	12.8	188

#	Article	lF	CITATIONS
37	Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability–High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials. JAMA Oncology, 2021, 7, 895.	7.1	184
38	Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study. Gastric Cancer, 2019, 22, 828-837.	5.3	181
39	Etiologic field effect: reappraisal of the field effect concept in cancer predisposition and progression. Modern Pathology, 2015, 28, 14-29.	5.5	172
40	Association of Aspirin and NSAID Use With Risk of Colorectal Cancer According to Genetic Variants. JAMA - Journal of the American Medical Association, 2015, 313, 1133.	7.4	171
41	Dietary Glycemic Load and Cancer Recurrence and Survival in Patients with Stage III Colon Cancer: Findings From CALGB 89803. Journal of the National Cancer Institute, 2012, 104, 1702-1711.	6.3	163
42	Safety, Costs, and Efficacy of Rapid Drug Desensitizations to Chemotherapy and Monoclonal Antibodies. Journal of Allergy and Clinical Immunology: in Practice, 2016, 4, 497-504.	3.8	156
43	Analysis of Heritability and Shared Heritability Based on Genome-Wide Association Studies for Thirteen Cancer Types. Journal of the National Cancer Institute, 2015, 107, djv279.	6.3	152
44	Irinotecan in the treatment of colorectal cancer. Cancer Treatment Reviews, 2006, 32, 491-503.	7.7	148
45	Association of Survival With Adherence to the American Cancer Society Nutrition and Physical Activity Guidelines for Cancer Survivors After Colon Cancer Diagnosis. JAMA Oncology, 2018, 4, 783.	7.1	147
46	Aspirin Use and Risk of Colorectal Cancer According to BRAF Mutation Status. JAMA - Journal of the American Medical Association, 2013, 309, 2563.	7.4	146
47	Genome-wide association study of colorectal cancer identifies six new susceptibility loci. Nature Communications, 2015, 6, 7138.	12.8	138
48	KEYNOTE-059 cohort 1: Efficacy and safety of pembrolizumab (pembro) monotherapy in patients with previously treated advanced gastric cancer Journal of Clinical Oncology, 2017, 35, 4003-4003.	1.6	134
49	KEYNOTE-585: Phase III study of perioperative chemotherapy with or without pembrolizumab for gastric cancer. Future Oncology, 2019, 15, 943-952.	2.4	133
50	Novel Common Genetic Susceptibility Loci for Colorectal Cancer. Journal of the National Cancer Institute, 2019, 111, 146-157.	6.3	129
51	Development and Validation of the PREMM <sub>5</sub> Model for Comprehensive Risk Assessment of Lynch Syndrome. Journal of Clinical Oncology, 2017, 35, 2165-2172.	1.6	126
52	Dietary Patterns and Risk of Colorectal Cancer: Analysis by Tumor Location and Molecular Subtypes. Gastroenterology, 2017, 152, 1944-1953.e1.	1.3	124
53	First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811. Future Oncology, 2021, 17, 491-501.	2.4	117
54	Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database. Journal of Clinical Oncology, 2016, 34, 144-150.	1.6	116

#	Article	IF	CITATIONS
55	Aspirin and COX-2 Inhibitor Use in Patients With Stage III Colon Cancer. Journal of the National Cancer Institute, 2015, 107, 345.	6.3	115
56	Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance). Journal of Clinical Oncology, 2017, 35, 3671-3677.	1.6	112
57	Aspirin Use and Colorectal Cancer Survival According to Tumor CD274 (Programmed Cell Death 1) Tj ETQq1 1	0.784314 r 1.6	gBT /Overlock
58	Diets That Promote Colon Inflammation Associate With Risk of Colorectal Carcinomas That Contain Fusobacterium nucleatum. Clinical Gastroenterology and Hepatology, 2018, 16, 1622-1631.e3.	4.4	103
59	Hormone Therapy Increases Risk of Ulcerative Colitis but not Crohn's Disease. Gastroenterology, 2012, 143, 1199-1206.	1.3	101
60	Characterization of Large Structural Genetic Mosaicism in Human Autosomes. American Journal of Human Genetics, 2015, 96, 487-497.	6.2	101
61	A phase II trial of gemcitabine in patients with advanced hepatocellular carcinoma. Cancer, 2002, 94, 3186-3191.	4.1	95
62	Dietary Patterns and Pancreatic Cancer Risk in Men and Women. Journal of the National Cancer Institute, 2005, 97, 518-524.	6.3	95
63	LIN28 cooperates with WNT signaling to drive invasive intestinal and colorectal adenocarcinoma in mice and humans. Genes and Development, 2015, 29, 1074-1086.	5.9	92
64	Development and validation of empirical indices to assess the insulinaemic potential of diet and lifestyle. British Journal of Nutrition, 2016, 116, 1787-1798.	2.3	91
65	Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33. Human Molecular Genetics, 2014, 23, 6616-6633.	2.9	90
66	Marine ω-3 polyunsaturated fatty acid intake and survival after colorectal cancer diagnosis. Gut, 2017, 66, 1790-1796.	12.1	89
67	Inherited DNA-Repair Defects in Colorectal Cancer. American Journal of Human Genetics, 2018, 102, 401-414.	6.2	89
68	Three new pancreatic cancer susceptibility signals identified on chromosomes 1q32.1, 5p15.33 and 8q24.21. Oncotarget, 2016, 7, 66328-66343.	1.8	88
69	Individual Patient Data Analysis of Progression-Free Survival Versus Overall Survival As a First-Line End Point for Metastatic Colorectal Cancer in Modern Randomized Trials: Findings From the Analysis and Research in Cancers of the Digestive System Database. Journal of Clinical Oncology, 2015, 33, 22-28.	1.6	87
70	Survival Among Patients With Pancreatic Cancer and Long-Standing or Recent-Onset Diabetes Mellitus. Journal of Clinical Oncology, 2015, 33, 29-35.	1.6	83
71	Multiplexed activation of endogenous genes by CRISPRa elicits potent antitumor immunity. Nature Immunology, 2019, 20, 1494-1505.	14.5	83
72	A Prospective Study of Duration of Smoking Cessation and Colorectal Cancer Risk by Epigenetics-related Tumor Classification. American Journal of Epidemiology, 2013, 178, 84-100.	3.4	81

#	Article	IF	CITATIONS
73	Associations between nut consumption and inflammatory biomarkers,. American Journal of Clinical Nutrition, 2016, 104, 722-728.	4.7	80
74	Association of Physical Activity by Type and Intensity With Digestive System Cancer Risk. JAMA Oncology, 2016, 2, 1146.	7.1	78
75	Cigarette Smoking and Pancreatic Cancer Survival. Journal of Clinical Oncology, 2017, 35, 1822-1828.	1.6	78
76	Endocrine-Exocrine Signaling Drives Obesity-Associated Pancreatic Ductal Adenocarcinoma. Cell, 2020, 181, 832-847.e18.	28.9	77
77	Sleep Duration Affects Risk for Ulcerative Colitis: A Prospective Cohort Study. Clinical Gastroenterology and Hepatology, 2014, 12, 1879-1886.	4.4	76
78	Composition, Spatial Characteristics, and Prognostic Significance of Myeloid Cell Infiltration in Pancreatic Cancer. Clinical Cancer Research, 2021, 27, 1069-1081.	7.0	75
79	Post Diagnosis Diet Quality and Colorectal Cancer Survival in Women. PLoS ONE, 2014, 9, e115377.	2.5	74
80	Early Life Body Fatness and Risk of Colorectal Cancer in U.S. Women and Men—Results from Two Large Cohort Studies. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 690-697.	2.5	74
81	Diabetes, Weight Change, and Pancreatic Cancer Risk. JAMA Oncology, 2020, 6, e202948.	7.1	72
82	Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial. Gastric Cancer, 2022, 25, 197-206.	5.3	72
83	Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer. JAMA - Journal of the American Medical Association, 2021, 325, 1277.	7.4	63
84	Common genetic variation and survival after colorectal cancer diagnosis: a genome-wide analysis. Carcinogenesis, 2016, 37, 87-95.	2.8	62
85	Association Between Inflammatory Diet Pattern and Risk of Colorectal Carcinoma Subtypes Classified by Immune Responses to Tumor. Gastroenterology, 2017, 153, 1517-1530.e14.	1.3	62
86	Coffee Intake, Recurrence, and Mortality in Stage III Colon Cancer: Results From CALGB 89803 (Alliance). Journal of Clinical Oncology, 2015, 33, 3598-3607.	1.6	60
87	A Transcriptome-Wide Association Study Identifies Novel Candidate Susceptibility Genes for Pancreatic Cancer. Journal of the National Cancer Institute, 2020, 112, 1003-1012.	6.3	59
88	Tumor LINE-1 Methylation Level and Microsatellite Instability in Relation to Colorectal Cancer Prognosis. Journal of the National Cancer Institute, 2014, 106, .	6.3	58
89	Simple Sugar and Sugar-Sweetened Beverage Intake During Adolescence and Risk of Colorectal Cancer Precursors. Gastroenterology, 2021, 161, 128-142.e20.	1.3	58
90	<scp><i>TERT</i></scp> gene harbors multiple variants associated with pancreatic cancer susceptibility. International Journal of Cancer, 2015, 137, 2175-2183.	5.1	57

#	Article	IF	CITATIONS
91	Association of dietary insulinemic potential and colorectal cancer risk in men and women. American Journal of Clinical Nutrition, 2018, 108, 363-370.	4.7	57
92	Progress and Opportunities in Molecular Pathological Epidemiology of Colorectal Premalignant Lesions. American Journal of Gastroenterology, 2014, 109, 1205-1214.	0.4	55
93	Neighborhood and Individual Socioeconomic Disadvantage and Survival Among Patients With Nonmetastatic Common Cancers. JAMA Network Open, 2021, 4, e2139593.	5.9	55
94	Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab. British Journal of Cancer, 2016, 115, 974-982.	6.4	53
95	Efficacy of Pembrolizumab Monotherapy for Advanced Gastric/Gastroesophageal Junction Cancer with Programmed Death Ligand 1 Combined Positive Score ≥10. Clinical Cancer Research, 2021, 27, 1923-1931.	7.0	53
96	Plasma Insulin-like Growth Factors, Insulin-like Binding Protein-3, and Outcome in Metastatic Colorectal Cancer: Results from Intergroup Trial N9741. Clinical Cancer Research, 2008, 14, 8263-8269.	7.0	52
97	Long-term status and change of body fat distribution, and risk of colorectal cancer: a prospective cohort study. International Journal of Epidemiology, 2016, 45, 871-883.	1.9	52
98	Marine ω-3 Polyunsaturated Fatty Acid and Fish Intake after Colon Cancer Diagnosis and Survival: CALGB 89803 (Alliance). Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 438-445.	2.5	52
99	Association Between Coffee Intake After Diagnosis of Colorectal Cancer and Reduced Mortality. Gastroenterology, 2018, 154, 916-926.e9.	1.3	52
100	Dietary glycemic load, carbohydrate, sugar, and colorectal cancer risk in men and women. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 138-47.	2.5	52
101	The Amount of Bifidobacterium Genus in Colorectal Carcinoma Tissue in Relation to Tumor Characteristics and Clinical Outcome. American Journal of Pathology, 2018, 188, 2839-2852.	3.8	51
102	Associations of Physical Activity With Survival and Progression in Metastatic Colorectal Cancer: Results From Cancer and Leukemia Group B (Alliance)/SWOG 80405. Journal of Clinical Oncology, 2019, 37, 2620-2631.	1.6	51
103	Nut Consumption and Survival in Patients With Stage III Colon Cancer: Results From CALGB 89803 (Alliance). Journal of Clinical Oncology, 2018, 36, 1112-1120.	1.6	50
104	Prediagnostic Plasma 25-Hydroxyvitamin D and Pancreatic Cancer Survival. Journal of Clinical Oncology, 2016, 34, 2899-2905.	1.6	49
105	Gene–Environment Interaction Involving Recently Identified Colorectal Cancer Susceptibility Loci. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 1824-1833.	2.5	48
106	Analysis of Survival Among Adults With Early-Onset Colorectal Cancer in the National Cancer Database. JAMA Network Open, 2021, 4, e2112539.	5.9	48
107	Coffee Consumption and Risk of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma by Sex: The Liver Cancer Pooling Project. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1398-1406.	2.5	47
108	Dietary patterns during high school and risk of colorectal adenoma in a cohort of middle-aged women. International Journal of Cancer, 2014, 134, 2458-2467.	5.1	46

#	Article	IF	CITATIONS
109	Pancreatic Cancer Risk Associated with Prediagnostic Plasma Levels of Leptin and Leptin Receptor Genetic Polymorphisms. Cancer Research, 2016, 76, 7160-7167.	0.9	46
110	Association Between Plasma Levels of Macrophage Inhibitory Cytokine-1 Before Diagnosis of Colorectal Cancer and Mortality. Gastroenterology, 2015, 149, 614-622.	1.3	44
111	Genomic Evolution after Chemoradiotherapy in Anal Squamous Cell Carcinoma. Clinical Cancer Research, 2017, 23, 3214-3222.	7.0	44
112	Plasma 25-Hydroxyvitamin D Levels and Survival in Patients with Advanced or Metastatic Colorectal Cancer: Findings from CALGB/SWOG 80405 (Alliance). Clinical Cancer Research, 2019, 25, 7497-7505.	7.0	44
113	Anorectal Cancer: Critical Anatomic and Staging Distinctions That Affect Use of Radiation Therapy. Radiographics, 2015, 35, 2090-2107.	3.3	42
114	Discovery and Features of an Alkylating Signature in Colorectal Cancer. Cancer Discovery, 2021, 11, 2446-2455.	9.4	42
115	Total Vitamin D Intake and Risks of Early-Onset Colorectal Cancer and Precursors. Gastroenterology, 2021, 161, 1208-1217.e9.	1.3	40
116	Leucocyte telomere length, genetic variants at the <i>TERT</i> gene region and risk of pancreatic cancer. Gut, 2017, 66, 1116-1122.	12.1	39
117	Calcium intake and risk of colorectal cancer according to expression status of calcium-sensing receptor (CASR). Gut, 2018, 67, 1475-1483.	12.1	39
118	Red Meat Intake, NAT2, and Risk of Colorectal Cancer: A Pooled Analysis of 11 Studies. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 198-205.	2.5	38
119	Plasma 25-Hydroxyvitamin D, Vitamin D Binding Protein, and Risk of Colorectal Cancer in the Nurses' Health Study. Cancer Prevention Research, 2016, 9, 664-672.	1.5	38
120	The association of tissue tumor mutational burden (tTMB) using the Foundation Medicine genomic platform with efficacy of pembrolizumab versus paclitaxel in patients (pts) with gastric cancer (GC) from KEYNOTE-061 Journal of Clinical Oncology, 2020, 38, 4537-4537.	1.6	38
121	Marine ω-3 Polyunsaturated Fatty Acids and Risk for Colorectal Cancer According to Microsatellite Instability. Journal of the National Cancer Institute, 2015, 107, .	6.3	37
122	Prediagnosis Plasma Adiponectin in Relation to Colorectal Cancer Risk According to <i>KRAS</i> Mutation Status. Journal of the National Cancer Institute, 2016, 108, djv363.	6.3	37
123	Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en Cancérologie Digestive Database. Journal of Clinical Oncology, 2017, 35, 1929-1937.	1.6	37
124	Urinary PGE-M Levels Are Associated with Risk of Colorectal Adenomas and Chemopreventive Response to Anti-Inflammatory Drugs. Cancer Prevention Research, 2014, 7, 758-765.	1.5	36
125	Association of Tumor Mutational Burden with Efficacy of Pembrolizumab±Chemotherapy as First-Line Therapy for Gastric Cancer in the Phase III KEYNOTE-062 Study. Clinical Cancer Research, 2022, 28, 3489-3498.	7.0	35
126	IGFBP3 Promoter Methylation in Colorectal Cancer: Relationship with Microsatellite Instability, CpG Island Methylator Phenotype, p53. Neoplasia, 2007, 9, 1091-1098.	5.3	34

#	Article	IF	CITATIONS
127	Physical Activity, Tumor PTGS2 Expression, and Survival in Patients with Colorectal Cancer. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 1142-1152.	2.5	34
128	Use of glucosamine and chondroitin supplements in relation to risk of colorectal cancer: Results from the Nurses' Health Study and Health Professionals followâ€up study. International Journal of Cancer, 2016, 139, 1949-1957.	5.1	33
129	KEYNOTE-859: a Phase III study of pembrolizumab plus chemotherapy in gastric/gastroesophageal junction adenocarcinoma. Future Oncology, 2021, 17, 2847-2855.	2.4	33
130	Impact of Physical Activity After Cancer Diagnosis on Survival in Patients With Recurrent Colon Cancer: Findings From CALGB 89803/Alliance. Clinical Colorectal Cancer, 2013, 12, 233-238.	2.3	31
131	Adulthood Weight Change and Risk of Colorectal Cancer in the Nurses' Health Study and Health Professionals Follow-up Study. Cancer Prevention Research, 2015, 8, 620-627.	1.5	31
132	Soluble tumour necrosis factor receptor type II and survival in colorectal cancer. British Journal of Cancer, 2016, 114, 995-1002.	6.4	31
133	Tumour budding, poorly differentiated clusters, and T-cell response in colorectal cancer. EBioMedicine, 2020, 57, 102860.	6.1	31
134	Pembrolizumab versus paclitaxel for previously treated patients with PD-L1–positive advanced gastric or gastroesophageal junction cancer (GC): Update from the phase III KEYNOTE-061 trial Journal of Clinical Oncology, 2020, 38, 4503-4503.	1.6	31
135	Plasma Inflammatory Markers and Risk of Advanced Colorectal Adenoma in Women. Cancer Prevention Research, 2016, 9, 27-34.	1.5	30
136	Association of Common Susceptibility Variants of Pancreatic Cancer in Higher-Risk Patients: A PACGENE Study. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 1185-1191.	2.5	29
137	Social integration and survival after diagnosis of colorectal cancer. Cancer, 2018, 124, 833-840.	4.1	29
138	Dairy consumption, plasma metabolites, and risk of type 2 diabetes. American Journal of Clinical Nutrition, 2021, 114, 163-174.	4.7	29
139	25-Hydroxyvitamin D Levels and Survival in Advanced Pancreatic Cancer: Findings From CALGB 80303 (Alliance). Journal of the National Cancer Institute, 2014, 106, .	6.3	28
140	Identification of a common variant with potential pleiotropic effect on risk of inflammatory bowel disease and colorectal cancer. Carcinogenesis, 2015, 36, 999-1007.	2.8	28
141	Phase 1 dose-escalation study of momelotinib, a Janus kinase 1/2 inhibitor, combined with gemcitabine and nab-paclitaxel in patients with previously untreated metastatic pancreatic ductal adenocarcinoma. Investigational New Drugs, 2019, 37, 159-165.	2.6	28
142	No Association Between Vitamin D Supplementation and Risk of Colorectal Adenomas or Serrated Polyps in a Randomized Trial. Clinical Gastroenterology and Hepatology, 2021, 19, 128-135.e6.	4.4	28
143	Alcohol, one-carbon nutrient intake, and risk of colorectal cancer according to tumor methylation level of IGF2 differentially methylated region. American Journal of Clinical Nutrition, 2014, 100, 1479-1488.	4.7	27
144	A Phase Ib/II Study of Ramucirumab in Combination with Emibetuzumab in Patients with Advanced Cancer. Clinical Cancer Research, 2019, 25, 5202-5211.	7.0	26

#	Article	IF	CITATIONS
145	The association of molecular biomarkers with efficacy of pembrolizumab versus paclitaxel in patients with gastric cancer (GC) from KEYNOTE-061 Journal of Clinical Oncology, 2020, 38, 4512-4512.	1.6	26
146	Associations of artificially sweetened beverage intake with disease recurrence and mortality in stage III colon cancer: Results from CALGB 89803 (Alliance). PLoS ONE, 2018, 13, e0199244.	2.5	25
147	Nut consumption and prostate cancer risk and mortality. British Journal of Cancer, 2016, 115, 371-374.	6.4	24
148	Association of Coffee Intake With Survival in Patients With Advanced or Metastatic Colorectal Cancer. JAMA Oncology, 2020, 6, 1713.	7.1	24
149	Survival in Young-Onset Metastatic Colorectal Cancer: Findings From Cancer and Leukemia Group B (Alliance)/SWOG 80405. Journal of the National Cancer Institute, 2022, 114, 427-435.	6.3	24
150	Assessment of a Dietary Questionnaire in Cancer Patients Receiving Cytotoxic Chemotherapy. Journal of Clinical Oncology, 2005, 23, 8453-8460.	1.6	23
151	Predicted 25(OH)D Score and Colorectal Cancer Risk According to Vitamin D Receptor Expression. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 1628-1637.	2.5	23
152	Prediagnostic Plasma Adiponectin and Survival among Patients with Colorectal Cancer. Cancer Prevention Research, 2015, 8, 1138-1145.	1.5	23
153	Sedentary behaviors and light-intensity activities in relation to colorectal cancer risk. International Journal of Cancer, 2016, 138, 2109-2117.	5.1	23
154	Spatial Organization and Prognostic Significance of NK and NKT-like Cells via Multimarker Analysis of the Colorectal Cancer Microenvironment. Cancer Immunology Research, 2022, 10, 215-227.	3.4	23
155	Null Association between Vitamin D and PSA Levels among Black Men in a Vitamin D Supplementation Trial. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 1944-1947.	2.5	22
156	Garlic intake and gastric cancer risk: Results from two large prospective US cohort studies. International Journal of Cancer, 2018, 143, 1047-1053.	5.1	22
157	Diabetes and Clinical Outcome in Patients With Metastatic Colorectal Cancer: CALGB 80405 (Alliance). JNCI Cancer Spectrum, 2020, 4, pkz078.	2.9	22
158	Prediagnosis Use of Statins Associates With Increased Survival Times of Patients With Pancreatic Cancer. Clinical Gastroenterology and Hepatology, 2018, 16, 1300-1306.e3.	4.4	21
159	Vitamin D status after colorectal cancer diagnosis and patient survival according to immune response to tumour. European Journal of Cancer, 2018, 103, 98-107.	2.8	21
160	Agnostic Pathway/Gene Set Analysis of Genome-Wide Association Data Identifies Associations for Pancreatic Cancer. Journal of the National Cancer Institute, 2019, 111, 557-567.	6.3	21
161	Continuity of transcriptomes among colorectal cancer subtypes based on meta-analysis. Genome Biology, 2018, 19, 142.	8.8	20
162	Calcium Intake and Survival after Colorectal Cancer Diagnosis. Clinical Cancer Research, 2019, 25, 1980-1988.	7.0	20

#	Article	IF	CITATIONS
163	Pembrolizumab (pembro) in microsatellite instability-high (MSI-H) advanced gastric/gastroesophageal junction (G/GEJ) cancer by line of therapy Journal of Clinical Oncology, 2020, 38, 430-430.	1.6	20
164	Diet- and Lifestyleâ€Based Prediction Models to Estimate Cancer Recurrence and Death in Patients With Stage III Colon Cancer (CALGB 89803/Alliance). Journal of Clinical Oncology, 2022, 40, 740-751.	1.6	20
165	Dietary Insulin Load and Cancer Recurrence and Survival in Patients With Stage III Colon Cancer: Findings From CALGB 89803 (Alliance). Journal of the National Cancer Institute, 2019, 111, 170-179.	6.3	19
166	Physical activity during adolescence and risk of colorectal adenoma later in life: results from the Nurses' Health Study II. British Journal of Cancer, 2019, 121, 86-94.	6.4	19
167	Genetic and Circulating Biomarker Data Improve Risk Prediction for Pancreatic Cancer in the General Population. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 999-1008.	2.5	19
168	CYP24A1 variant modifies the association between use of oestrogen plus progestogen therapy and colorectal cancer risk. British Journal of Cancer, 2016, 114, 221-229.	6.4	18
169	Tumor SQSTM1 (p62) expression and T cells in colorectal cancer. Oncolmmunology, 2017, 6, e1284720.	4.6	18
170	A Study of Thymidylate Synthase Expression as a Biomarker for Resectable Colon Cancer: Alliance (Cancer and Leukemia Group B) 9581 and 89803. Oncologist, 2017, 22, 107-114.	3.7	18
171	Comparison of Dietary and Lifestyle Habits Among Stage III and Metastatic Colorectal Cancer Patients: Findings from CALGB 89803 and CALGB 80405. Clinical Colorectal Cancer, 2013, 12, 95-102.	2.3	17
172	A Prospective Study of Smoking and Risk of Synchronous Colorectal Cancers. American Journal of Gastroenterology, 2017, 112, 493-501.	0.4	17
173	Dietary glycemic and insulin scores and colorectal cancer survival by tumor molecular biomarkers. International Journal of Cancer, 2017, 140, 2648-2656.	5.1	17
174	Genetic variation in the ADIPOQ gene, adiponectin concentrations and risk of colorectal cancer: a Mendelian Randomization analysis using data from three large cohort studies. European Journal of Epidemiology, 2017, 32, 419-430.	5.7	17
175	Prognostic association of PTGS2 (COX-2) over-expression according to BRAF mutation status in colorectal cancer: Results from two prospective cohorts and CALGB 89803 (Alliance) trial. European Journal of Cancer, 2019, 111, 82-93.	2.8	17
176	Endogenous sex hormones and colorectal cancer survival among men and women. International Journal of Cancer, 2020, 147, 920-930.	5.1	17
177	Effect of Exercise or Metformin on Biomarkers of Inflammation in Breast and Colorectal Cancer: A Randomized Trial. Cancer Prevention Research, 2020, 13, 1055-1062.	1.5	17
178	Multicenter double-blind randomized phase II: FOLFOX + ziv-aflibercept/placebo for patients (pts) with chemo-naive metastatic esophagogastric adenocarcinoma (MEGA) Journal of Clinical Oncology, 2016, 34, 4-4.	1.6	17
179	Plasma 25-Hydroxyvitamin D and Risk of Colorectal Cancer after Adjusting for Inflammatory Markers. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 2175-2180.	2.5	16
180	Oral Contraceptive Use and Colorectal Cancer in the Nurses' Health Study I and II. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1214-1221.	2.5	16

#	Article	IF	CITATIONS
181	Post-diagnosis dietary insulinemic potential and survival outcomes among colorectal cancer patients. BMC Cancer, 2020, 20, 817.	2.6	16
182	The Joint Association of Eating Frequency and Diet Quality With Colorectal Cancer Risk in the Health Professionals Follow-up Study. American Journal of Epidemiology, 2012, 175, 664-672.	3.4	14
183	FOLFOX plus zivâ€aflibercept or placebo in firstâ€line metastatic esophagogastric adenocarcinoma: A doubleâ€blind, randomized, multicenter phase 2 trial. Cancer, 2019, 125, 2213-2221.	4.1	14
184	Randomized Phase II Trial of Exercise, Metformin, or Both on Metabolic Biomarkers in Colorectal and Breast Cancer Survivors. JNCI Cancer Spectrum, 2020, 4, pkz096.	2.9	14
185	Ramucirumab (R) plus pembrolizumab (P) in treatment naive and previously treated advanced gastric or gastroesophageal junction (C/GEJ) adenocarcinoma: A multi-disease phase I study Journal of Clinical Oncology, 2017, 35, 4046-4046.	1.6	14
186	Efficacy of pembrolizumab (pembro) monotherapy versus chemotherapy for PD-L1–positive (CPS ≥10) advanced G/GEJ cancer in the phase II KEYNOTE-059 (cohort 1) and phase III KEYNOTE-061 and KEYNOTE-062 studies Journal of Clinical Oncology, 2020, 38, 427-427.	1.6	13
187	Joint Effects of Colorectal Cancer Susceptibility Loci, Circulating 25-Hydroxyvitamin D and Risk of Colorectal Cancer. PLoS ONE, 2014, 9, e92212.	2.5	12
188	Dietary Intake of Branched-Chain Amino Acids and Risk of Colorectal Cancer. Cancer Prevention Research, 2020, 13, 65-72.	1.5	12
189	Measuring the Impact of Academic Cancer Network Development on Clinical Integration, Quality of Care, and Patient Satisfaction. Journal of Oncology Practice, 2018, 14, e823-e833.	2.5	11
190	Identification of Plasma Lipid Metabolites Associated with Nut Consumption in US Men and Women. Journal of Nutrition, 2019, 149, 1215-1221.	2.9	11
191	Calcium Intake and Risk of Colorectal Cancer According to Tumor-infiltrating T Cells. Cancer Prevention Research, 2019, 12, 283-294.	1.5	11
192	Risk Factors and Incidence of Colorectal Cancer According to Major Molecular Subtypes. JNCI Cancer Spectrum, 2021, 5, pkaa089.	2.9	11
193	Abstract CT167: Pooled analysis of drug-related interstitial lung disease (ILD) in 8 single-arm trastuzumab deruxtecan (T-DXd) studies. Cancer Research, 2021, 81, CT167-CT167.	0.9	11
194	Risk of Hypercalcemia in Blacks Taking Hydrochlorothiazide and Vitamin D. American Journal of Medicine, 2014, 127, 772-778.	1.5	10
195	Grain Intake and Clinical Outcome in Stage III Colon Cancer: Results From CALGB 89803 (Alliance). JNCI Cancer Spectrum, 2018, 2, pky017.	2.9	10
196	Prognostic Utility of Molecular Factors by Age at Diagnosis of Colorectal Cancer. Clinical Cancer Research, 2016, 22, 1489-1498.	7.0	9
197	Prediagnostic Circulating Concentrations of Vitamin D Binding Protein and Survival among Patients with Colorectal Cancer. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 2323-2331.	2.5	9
198	Unrestrained eating behavior and risk of digestive system cancers: a prospective cohort study. American Journal of Clinical Nutrition, 2021, 114, 1612-1624.	4.7	9

#	Article	IF	CITATIONS
199	Prediagnostic Inflammation and Pancreatic Cancer Survival. Journal of the National Cancer Institute, 2021, 113, 1186-1193.	6.3	9
200	Hepcidin-regulating iron metabolism genes and pancreatic ductal adenocarcinoma: a pathway analysis of genome-wide association studies. American Journal of Clinical Nutrition, 2021, 114, 1408-1417.	4.7	9
201	Body Mass Index and Weight Loss in Metastatic Colorectal Cancer in CALGB (Alliance)/SWOG 80405. JNCI Cancer Spectrum, 2020, 4, pkaa024.	2.9	8
202	Association of Diet Quality With Survival Among People With Metastatic Colorectal Cancer in the Cancer and Leukemia B and Southwest Oncology Group 80405 Trial. JAMA Network Open, 2020, 3, e2023500.	5.9	8
203	Insulin-Like Growth Factor-1 Receptor Expression and Disease Recurrence and Survival in Patients with Resected Pancreatic Ductal Adenocarcinoma. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 1586-1595.	2.5	8
204	Effects of Vitamin D Supplementation on C-peptide and 25-hydroxyvitamin D Concentrations at 3 and 6 Months. Scientific Reports, 2015, 5, 10411.	3.3	7
205	Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061. Gastric Cancer, 2021, 24, 1330-1340.	5.3	7
206	Association Between Aspirin Use and Gastric Adenocarcinoma: A Prospective Cohort Study. Cancer Prevention Research, 2022, 15, 265-272.	1.5	7
207	Long-Term Survival and Causes of Death After Diagnoses of Common Cancers in 3 Cohorts of US Health Professionals. JNCI Cancer Spectrum, 2022, 6, .	2.9	7
208	IGF-Binding Proteins, Adiponectin, and Survival in Metastatic Colorectal Cancer: Results From CALGB (Alliance)/SWOG 80405. JNCI Cancer Spectrum, 2021, 5, pkaa074.	2.9	6
209	Preexisting Type 2 Diabetes and Survival among Patients with Colorectal Cancer. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 757-764.	2.5	6
210	Myths about diversity in clinical trials reduce return on investment for industry. Nature Medicine, 2022, 28, 1520-1522.	30.7	6
211	Fish and marine fatty acids intakes, the <i>FADS</i> genotypes and long-term weight gain: a prospective cohort study. BMJ Open, 2019, 9, e022877.	1.9	5
212	The Diet of Higher Insulinemic Potential Is Not Associated with Worse Survival in Patients with Stage III Colon Cancer (Alliance). Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 1692-1695.	2.5	5
213	Unrestrained eating behavior and risk of mortality: A prospective cohort study. Clinical Nutrition, 2021, 40, 5419-5429.	5.0	5
214	Marital Status, Living Arrangement, and Cancer Recurrence and Survival in Patients with Stage III Colon Cancer: Findings from CALGB 89803 (Alliance). Oncologist, 2022, 27, e494-e505.	3.7	5
215	Reported behavior of eating anything at anytime and risk of colorectal cancer in women. International Journal of Cancer, 2012, 130, 1395-1400.	5.1	4
216	Influence of genetic variation in the vitamin D pathway on plasma 25-hydroxyvitamin D3 levels and survival among patients with metastatic colorectal cancer. Cancer Causes and Control, 2019, 30, 757-765.	1.8	4

#	Article	IF	CITATIONS
217	Race, Income, and Survival in Stage III Colon Cancer: CALGB 89803 (Alliance). JNCI Cancer Spectrum, 2021, 5, pkab034.	2.9	4
218	KEYNOTE-811 pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction cancer (mG/GEJc): A double-blind, randomized, placebo-controlled phase III study Journal of Clinical Oncology, 2020, 38, TPS463-TPS463.	1.6	4
219	Reduction of parathyroid hormone with vitamin D supplementation in blacks: a randomized controlled trial. BMC Nutrition, 2015, 1, .	1.6	3
220	Immune profiling and clinical outcomes in patients treated with ramucirumab and pembrolizumab in phase I study JVDF Journal of Clinical Oncology, 2020, 38, 3089-3089.	1.6	3
221	A phase II trial of [fam-] trastuzumab deruxtecan (T-DXd, DS-8201a) in subjects with HER2-positive, unresectable, or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma Journal of Clinical Oncology, 2020, 38, TPS460-TPS460.	1.6	3
222	Coffee Intake of Colorectal Cancer Patients and Prognosis According to Histopathologic Lymphocytic Reaction and T-Cell Infiltrates. Mayo Clinic Proceedings, 2022, 97, 124-133.	3.0	3
223	Age and comorbidity association with survival outcomes in metastatic colorectal cancer: CALGB 80405 analysis. Journal of Geriatric Oncology, 2022, 13, 469-479.	1.0	3
224	Associations Between Unprocessed Red Meat and Processed Meat With Risk of Recurrence and Mortality in Patients With Stage III Colon Cancer. JAMA Network Open, 2022, 5, e220145.	5.9	3
225	Pharmacogenetic study in gastric cancer patients treated with adjuvant fluorouracil/leucovorin or epirubicin/cisplatin/fluorouracil before and after chemoradiation on CALGB 80101 (Alliance). Pharmacogenetics and Genomics, 2021, Publish Ahead of Print, 215-220.	1.5	2
226	A randomized, double-blind, placebo-controlled phase III study of cisplatin plus a fluoropyrimidine with or without ramucirumab as first-line therapy in patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma (RAINFALL, NCT02314117) Journal of Clinical Oncology, 2016, 34, TPS178-TPS178.	1.6	2
227	Celecoxib in addition to standard adjuvant therapy with 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX) in stage III colon cancer: Results from CALGB/SWOG 80702 Journal of Clinical Oncology, 2020, 38, 4003-4003.	1.6	2
228	Cetuximab and Irinotecan With or Without Bevacizumab in Refractory Metastatic Colorectal Cancer: BOND-3, an ACCRU Network Randomized Clinical Trial. Oncologist, 2022, 27, 292-298.	3.7	2
229	Multicenter, randomized phase II trial of physical activity (PA), metformin (Met), or the combination on metabolic biomarkers in stage I-III colorectal (CRC) and breast cancer (BC) survivors Journal of Clinical Oncology, 2017, 35, 10059-10059.	1.6	1
230	How to improve toxicity evaluation in clinical trials? Testing new metrics from irinotecan or oxaliplatin-based treatments in metastatic colorectal cancer (mCRC): A pooled analysis from 2,349 patients in ARCAD database Journal of Clinical Oncology, 2020, 38, 89-89.	1.6	1
231	KEYNOTE-059 cohort 1: Pembrolizumab (Pembro) monotherapy in previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer in patients (Pts) with PD-L1+ tumors—Asian subgroup analysis Journal of Clinical Oncology, 2018, 36, 723-723.	1.6	1
232	Effect of post-discontinuation therapy (PDT) on survival in metastatic gastric-gastroesophageal junction (G-GEJ) adenocarcinoma patients from the RAINFALL trial: An exploratory analysis Journal of Clinical Oncology, 2018, 36, 4044-4044.	1.6	1
233	Cancer of the Appendix. , 2006, , 410-417.		0
234	Response. Journal of the National Cancer Institute, 2014, 106, dju181-dju181.	6.3	0

#	Article	IF	CITATIONS
235	Response. Journal of the National Cancer Institute, 2015, 107, djv150-djv150.	6.3	0
236	Reply to L. Fornaro et al. Journal of Clinical Oncology, 2018, 36, 1179-1180.	1.6	0
237	Influence of dietary insulin scores on survival in patients with metastatic colorectal cancer (mCRC): Findings from CALGB (Alliance) 80405 Journal of Clinical Oncology, 2021, 39, 3568-3568.	1.6	Ο
238	Dietary fat in relation to overall and progression-free survival among patients (pts) with advanced or metastatic colorectal cancer (CRC): Data from CALGB 80405 (Alliance) Journal of Clinical Oncology, 2021, 39, 3588-3588.	1.6	0
239	Abstract 898: Survival for patients with early-onset colorectal cancer - An overall survival analysis from the National Cancer Database, 2004-2015. , 2021, , .		0
240	Prognostic value of tumor deposits in stage III colon cancer patients, a post-hoc analysis of CALGB/SWOG 80702 phase III study Journal of Clinical Oncology, 2021, 39, 10-10.	1.6	0
241	Aspirin Use and Risk for Colorectal Adenoma. Annals of Internal Medicine, 2004, 141, 406.	3.9	0
242	Novel driver genes and genomic predictors of immune infiltrates in colorectal cancer Journal of Clinical Oncology, 2016, 34, 557-557.	1.6	0
243	Real-world adherence and treatment discontinuation with trifluridine/tipiracil (FTD-TPI) compared with regorafenib (REC) for the treatment of metastatic colorectal cancer (mCRC) Journal of Clinical Oncology, 2017, 35, e15000-e15000.	1.6	0
244	Body Mass Index and Other Anthropomorphic Variables in Relation to Risk of Colorectal Carcinoma Subtypes Classified by Tumor Differentiation Status. FASEB Journal, 2018, 32, 677.9.	0.5	0
245	Tumor Nuclear <i>YAP1</i> Expression Status and Molecular Characteristics in relation to Immune Response to Colorectal Carcinoma. FASEB Journal, 2018, 32, 406.5.	0.5	0
246	Multiplexed Immunoâ€Profiling of the Colorectal Carcinoma Microenvironment Using Archival Human Tissue. FASEB Journal, 2018, 32, 818.4.	0.5	0
247	Bifidobacterium Genus in Colorectal Carcinoma Tissue in relation to Tumor Characteristics and Patient Survival. FASEB Journal, 2018, 32, 407.3.	0.5	0
248	Long-term cancer survival in cohorts of U.S. health professionals Journal of Clinical Oncology, 2020, 38, 12075-12075.	1.6	0
249	Efficacy of bevacizumab-based treatment in early-onset treatment-naÃ <sup>-</sup> ve metastatic colorectal cancer patients: An ARCAD database analysis Journal of Clinical Oncology, 2022, 40, 101-101.	1.6	0
250	Aspirin, the new targeted therapy in colorectal cancer. Clinical Advances in Hematology and Oncology, 2014, 12, 186-9.	0.3	0